Antiva Biosciences Company

Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection. The company's medicinal chemistry platform focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV, and animal retroviruses, enabling patients to recover from HPV-related diseases and other viruses.

Total Funding: $87,346,025
Headquarters: Del Mar, California, United States
Funding Status: Late Stage Venture
Employee Number: 11-50
Estimated Revenue: $1M to $10M
Investment Stage: N/A
Last Funding Type: Series D
Number Of Exists: N/A
Technology: Cancer
Investor Type: N/A
Last Funding Date: 2021-11-02
Investors Number: 18
Founded Date: 01-01-2012
Industry: General Health Care